Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 19;11(9):e007630. doi: 10.1136/jitc-2023-007630

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Survival outcomes after re-introduction of systemic treatments for locoregional tumor recurrence. Following locoregional tumor recurrence systemic treatment with TT prolonged RFS as compared with CPI therapy (median RFS2: 24.0 months, 95% CI 8.6 to 39.4 vs 6.0 months, 95% CI 3.2 to 8.7, p=0.001) (A). As most patients switched treatment modalities upon locoregional recurrence there was no statistically significant difference in cumulative progression-free survival between patients who received CPI or TT as second treatment (median cPFS: 49.0 vs 28.0 months, p=0.11) (B). Patients with fully resected locoregional recurrence, who received a second adjuvant treatment with TT showed a significantly longer RFS as compared with patients who received a second adjuvant CPI therapy (median RFS2: 41.0 vs 6.0 months, p=0.009) (C). By contrast, patients who received a second adjuvant treatment for resected stage IV disease presented with a shorter RFS compared with patients with adjuvant treatment for resected stage III. Also, for these patients no statistically significant RFS has been observed between either adjuvant anti-PD1, BRAF/MEKi or ipi+nivo (median RFS3: 3 vs 11 months vs NR, p=0.37) (D). cPFS, cumulative progression-free survival; CPI, checkpoint inhibitor; RFS, recurrence-free survival; TT, targeted therapy.